首页 > 最新文献

Fukuoka igaku zasshi = Hukuoka acta medica最新文献

英文 中文
[Sphingolipidosis]. [Sphingolipidosis]。
Pub Date : 2020-02-02 DOI: 10.32388/xbq9xk
T. Kobayashi
{"title":"[Sphingolipidosis].","authors":"T. Kobayashi","doi":"10.32388/xbq9xk","DOIUrl":"https://doi.org/10.32388/xbq9xk","url":null,"abstract":"","PeriodicalId":12665,"journal":{"name":"Fukuoka igaku zasshi = Hukuoka acta medica","volume":"1 1","pages":"151-5"},"PeriodicalIF":0.0,"publicationDate":"2020-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83578134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Completely Responsive Multiple Liver Recurrence of Colon Cancer Treated Using Chemotherapy with Oral S-1 and Oxaliplatin Plus Bevacizumab : A Case Report. 口服S-1和奥沙利铂加贝伐单抗化疗治疗多发性肝脏复发结肠癌的完全应答:1例报告
Pub Date : 2017-01-25 DOI: 10.15017/1808303
A. Kabashima, K. Kimura, K. Sanefuji, S. Maekawa
Although chemotherapy with oral S-1and oxaliplatin (SOX) plus bevacizumab (bev) is safe andfeasible for patients with advanced or recurrent colorectal cancer, it is difficult to achieve a completeresponse (CR) using only chemotherapy. A 67-year-old man underwent endoscopic mucosal resectionand additional sigmoidectomy (D2 dissection) for submucosal invasive sigmoid colon cancer. Multipleliver metastases were diagnosed 1.5 years later, and chemotherapy with SOX + bev was initiated.Computed tomography (CT) after the end of the third course revealed reduced liver recurrence. Livermetastases could not be identified using CT after the end of the sixth course. Grade 1peripheralneuropathy was the only side effect of this regimen. Subsequently, the chemotherapy regimen waschanged to oral S-1. CT evaluation revealed that there was no recurrence at 6 months after theregimen change.
虽然口服s -1和奥沙利铂(SOX)加贝伐单抗(bevizumab)化疗对于晚期或复发性结直肠癌患者是安全可行的,但仅使用化疗很难达到完全缓解(CR)。一位67岁的男性接受内镜粘膜切除术和附加乙状结肠切除术(D2夹层)治疗粘膜下浸润性乙状结肠癌。1年半后被诊断为多发性转移,并开始用SOX + bev化疗。第三疗程结束后的计算机断层扫描(CT)显示肝脏复发减少。在第6个疗程结束后,CT无法发现肝转移。1级周围神经病变是该方案唯一的副作用。随后化疗方案改为口服S-1。CT检查显示改变方案后6个月无复发。
{"title":"Completely Responsive Multiple Liver Recurrence of Colon Cancer Treated Using Chemotherapy with Oral S-1 and Oxaliplatin Plus Bevacizumab : A Case Report.","authors":"A. Kabashima, K. Kimura, K. Sanefuji, S. Maekawa","doi":"10.15017/1808303","DOIUrl":"https://doi.org/10.15017/1808303","url":null,"abstract":"Although chemotherapy with oral S-1and oxaliplatin (SOX) plus bevacizumab (bev) is safe and\u0000feasible for patients with advanced or recurrent colorectal cancer, it is difficult to achieve a complete\u0000response (CR) using only chemotherapy. A 67-year-old man underwent endoscopic mucosal resection\u0000and additional sigmoidectomy (D2 dissection) for submucosal invasive sigmoid colon cancer. Multiple\u0000liver metastases were diagnosed 1.5 years later, and chemotherapy with SOX + bev was initiated.\u0000Computed tomography (CT) after the end of the third course revealed reduced liver recurrence. Liver\u0000metastases could not be identified using CT after the end of the sixth course. Grade 1peripheral\u0000neuropathy was the only side effect of this regimen. Subsequently, the chemotherapy regimen was\u0000changed to oral S-1. CT evaluation revealed that there was no recurrence at 6 months after the\u0000regimen change.","PeriodicalId":12665,"journal":{"name":"Fukuoka igaku zasshi = Hukuoka acta medica","volume":"32 1","pages":"8-13"},"PeriodicalIF":0.0,"publicationDate":"2017-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76484397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Completely Responsive Multiple Liver Recurrence of Colon Cancer Treated Using Chemotherapy with Oral S-1 and Oxaliplatin Plus Bevacizumab : A Case Report. 口服S-1和奥沙利铂加贝伐单抗化疗治疗多发性肝脏复发结肠癌的完全应答:1例报告
Akira Kabashima, Koichi Kimura, Kensakuet Sanefuji, Soichiro Maekawa

Although chemotherapy with oral S-1and oxaliplatin (SOX) plus bevacizumab (bev) is safe andfeasible for patients with advanced or recurrent colorectal cancer, it is difficult to achieve a completeresponse (CR) using only chemotherapy. A 67-year-old man underwent endoscopic mucosal resectionand additional sigmoidectomy (D2 dissection) for submucosal invasive sigmoid colon cancer. Multipleliver metastases were diagnosed 1.5 years later, and chemotherapy with SOX + bev was initiated.Computed tomography (CT) after the end of the third course revealed reduced liver recurrence. Livermetastases could not be identified using CT after the end of the sixth course. Grade 1peripheralneuropathy was the only side effect of this regimen. Subsequently, the chemotherapy regimen waschanged to oral S-1. CT evaluation revealed that there was no recurrence at 6 months after theregimen change.

虽然口服s -1和奥沙利铂(SOX)加贝伐单抗(bevizumab)化疗对于晚期或复发性结直肠癌患者是安全可行的,但仅使用化疗很难达到完全缓解(CR)。一位67岁的男性接受内镜粘膜切除术和附加乙状结肠切除术(D2夹层)治疗粘膜下浸润性乙状结肠癌。1年半后被诊断为多发性转移,并开始用SOX + bev化疗。第三疗程结束后的计算机断层扫描(CT)显示肝脏复发减少。在第6个疗程结束后,CT无法发现肝转移。1级周围神经病变是该方案唯一的副作用。随后化疗方案改为口服S-1。CT检查显示改变方案后6个月无复发。
{"title":"Completely Responsive Multiple Liver Recurrence of Colon Cancer Treated Using Chemotherapy with Oral S-1 and Oxaliplatin Plus Bevacizumab : A Case Report.","authors":"Akira Kabashima,&nbsp;Koichi Kimura,&nbsp;Kensakuet Sanefuji,&nbsp;Soichiro Maekawa","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Although chemotherapy with oral S-1and oxaliplatin (SOX) plus bevacizumab (bev) is safe and\u0000feasible for patients with advanced or recurrent colorectal cancer, it is difficult to achieve a complete\u0000response (CR) using only chemotherapy. A 67-year-old man underwent endoscopic mucosal resection\u0000and additional sigmoidectomy (D2 dissection) for submucosal invasive sigmoid colon cancer. Multiple\u0000liver metastases were diagnosed 1.5 years later, and chemotherapy with SOX + bev was initiated.\u0000Computed tomography (CT) after the end of the third course revealed reduced liver recurrence. Liver\u0000metastases could not be identified using CT after the end of the sixth course. Grade 1peripheral\u0000neuropathy was the only side effect of this regimen. Subsequently, the chemotherapy regimen was\u0000changed to oral S-1. CT evaluation revealed that there was no recurrence at 6 months after the\u0000regimen change.</p>","PeriodicalId":12665,"journal":{"name":"Fukuoka igaku zasshi = Hukuoka acta medica","volume":"108 1","pages":"8-13"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35329764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bone and Joint Diseases in Present and Future. 骨骼和关节疾病的现在和未来。
Yasuharu Nakashima, Ken Okazak, Koichiet Nakayama, Seiji Okada, Hideki Mizu-uchi

With the increase of elderly population, orthopaedic surgeons need to deal with the diseases relatedto aging, such as joint disorders and fragility fractures. The number of total joint replacements, forexample, is two times more than it was 10 years ago. With these backgrounds, the JapaneseOrthopaedic Association (JOA) has proposed the concept of locomotive syndrome; conditions underwhich the elderly have been receiving care services due to problems of the locomotive organs. Toprevent geriatric or disuse syndrome, JOA is currently providing the care‒prevention programs suchas the loco-check and loco-training. Recent advances in the orthopaedic fields were cited in this review article, including the topics ofnew biomaterials, regenerative medicine of cartilage, spinal cord injury and computer assistedorthopaedic surgery. These new technologies and knowledge are changing or have potential to changethe future orthopedic medical care.

随着老年人口的增加,骨科医生需要处理与老龄化有关的疾病,如关节疾病和脆性骨折。例如,关节置换手术的总数是10年前的两倍多。在这些背景下,日本骨科协会(JOA)提出了机车综合征的概念;由于机车器官的问题,老年人一直在接受护理服务的情况。为了预防老年病或废用综合症,JOA目前正在提供诸如本地检查和本地培训等护理预防项目。本文综述了近年来骨科领域的最新进展,包括新型生物材料、软骨再生医学、脊髓损伤和计算机辅助骨科手术。这些新技术和新知识正在改变或有潜力改变未来的骨科医疗保健。
{"title":"Bone and Joint Diseases in Present and Future.","authors":"Yasuharu Nakashima,&nbsp;Ken Okazak,&nbsp;Koichiet Nakayama,&nbsp;Seiji Okada,&nbsp;Hideki Mizu-uchi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>With the increase of elderly population, orthopaedic surgeons need to deal with the diseases related\u0000to aging, such as joint disorders and fragility fractures. The number of total joint replacements, for\u0000example, is two times more than it was 10 years ago. With these backgrounds, the Japanese\u0000Orthopaedic Association (JOA) has proposed the concept of locomotive syndrome; conditions under\u0000which the elderly have been receiving care services due to problems of the locomotive organs. To\u0000prevent geriatric or disuse syndrome, JOA is currently providing the care‒prevention programs such\u0000as the loco-check and loco-training. Recent advances in the orthopaedic fields were cited in this review article, including the topics of\u0000new biomaterials, regenerative medicine of cartilage, spinal cord injury and computer assisted\u0000orthopaedic surgery. These new technologies and knowledge are changing or have potential to change\u0000the future orthopedic medical care.</p>","PeriodicalId":12665,"journal":{"name":"Fukuoka igaku zasshi = Hukuoka acta medica","volume":"108 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35635195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Present Situation and Clinical Topics of Ventricular Assist Device and Heart Transplantation in Japan. 日本心室辅助装置与心脏移植的现状及临床课题。
Yoshihisa Tanoue, Akira Shiose

Surgical treatment for heart failure includes coronary artery bypass grafting to ischemic heartdisease, valvular disease surgery such as mitral valvuloplasty, left ventricular restoration, ventricularassist device (VAD), and heart transplantation. In addition, HeartSheet which is regenerative medicineusing autologous skeletal myoblast sheets has been started from the spring of 2016. Formal insurancereimbursement of implantable LVAD was obtained in April 2011, and the life prognosis of patientswith severe heart failure improved markedly. However, the indication for implantable LVAD is limitedto bridge use for heart transplantation. Implantable LVAD cannot be implanted in patients over 65years old under health insurance because the adaptive age of heart transplantation in Japan is under 65years old. It is a problem that the indication of implantable LVAD is identical to that of hearttransplantation. Clinical trial of destination therapy is in progress for the purpose of optimizing theimplantable LVAD indication. I strongly pray that VAD treatment including destination therapy (DT)and transplant medical treatment based on good intentions will be accepted socially as generaltreatment.

心力衰竭的外科治疗包括缺血性心脏病冠状动脉搭桥移植术、二尖瓣成形术等瓣膜疾病手术、左心室修复、心室辅助装置(VAD)和心脏移植。此外,HeartSheet是一种使用自体骨骼肌成肌细胞片的再生医学,已于2016年春季启动。2011年4月获得植入式LVAD的正式保险报销,重度心力衰竭患者的生活预后明显改善。然而,植入式左室辅助器的适应症仅限于心脏移植的桥接使用。由于日本心脏移植的适应年龄在65岁以下,因此不能在65岁以上的健康保险患者中植入植入式左心室辅助器。植入式左室辅助器的适应症与心脏移植的适应症相同是一个问题。目的治疗的临床试验正在进行中,目的是优化植入式LVAD的适应症。希望包括目的治疗(destination therapy, DT)和移植治疗在内的VAD治疗能够被社会接受。”
{"title":"The Present Situation and Clinical Topics of Ventricular Assist Device and Heart Transplantation in Japan.","authors":"Yoshihisa Tanoue,&nbsp;Akira Shiose","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Surgical treatment for heart failure includes coronary artery bypass grafting to ischemic heart\u0000disease, valvular disease surgery such as mitral valvuloplasty, left ventricular restoration, ventricular\u0000assist device (VAD), and heart transplantation. In addition, HeartSheet which is regenerative medicine\u0000using autologous skeletal myoblast sheets has been started from the spring of 2016. Formal insurance\u0000reimbursement of implantable LVAD was obtained in April 2011, and the life prognosis of patients\u0000with severe heart failure improved markedly. However, the indication for implantable LVAD is limited\u0000to bridge use for heart transplantation. Implantable LVAD cannot be implanted in patients over 65\u0000years old under health insurance because the adaptive age of heart transplantation in Japan is under 65\u0000years old. It is a problem that the indication of implantable LVAD is identical to that of heart\u0000transplantation. Clinical trial of destination therapy is in progress for the purpose of optimizing the\u0000implantable LVAD indication. I strongly pray that VAD treatment including destination therapy (DT)\u0000and transplant medical treatment based on good intentions will be accepted socially as general\u0000treatment.</p>","PeriodicalId":12665,"journal":{"name":"Fukuoka igaku zasshi = Hukuoka acta medica","volume":"107 12","pages":"213-22"},"PeriodicalIF":0.0,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35240054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Natural Immunity and Ocular Inflammation. 自然免疫与眼部炎症。
Koh-Hei Sonoda

We have focused on the role of innate immunity during the formation oföchoroidal neovascularization(CNV) -related diseasesù. Inflammation affects the formation and the progression of variousvitreoretinal diseases. We performed a comprehensive analysis of inflammatory immune mediators inthe vitreous fluids with diabetic macular edema, proliferative diabetic retinopathy, branch retinal veinocclusion, central retinal vein occlusion and rhegmatogenous retinal detachment. The concentrationsof 20 soluble factors (nine cytokines, six chemokines, and five growth factors) were measuredsimultaneously by multiplex bead analysis system. Out of 20 soluble factors, three factors :interleukin-6 (IL-6), interleukin-8 (IL-8), and monocyte chemoattractant protein-1 (MCP-1) weresignificantly elevated in all groups of vitreoretinal diseases compared with control group. According tothe correlation analysis in the individual patientʼs level, these three factors that were simultaneouslyincreased, did not show any independent upregulation in all the examined diseases.We also elucidated the role of natural killer (NK)T cells, which restricted CD1 molecule andparticipate in the innate immune response, in laser-induced experimental CNV. We examined CNVformation in independent two NKT cell-deficient mice, either CD1 knockout (KO) mice or Ja18 KOmice, and found that both KO mice showed significant reduction of experimental CNV.During the clinical process of CNV-related diseases, not only CNV formation, subretinal scaring isthought to be another important step. We thus established the experimental model of subretinalscaring by injecting peritoneal exudating macrophages into subretinal space. Subretinal fibrous tissuewas observed by fundus scope in PEC-inoculated mice after seven days. The tissue was consisted ofmonotonous and low cell-density area, which expressed a-SMA with collagen synthesis. BecausePEC-inoculated MCP-1 KO mice showed less amount of glial residual, not only exogenousmacrophages, but also intrinsic macrophages are critical. Activated macrophages directly inducedmyofibrotic changes in RPE cells in vitro.

我们关注先天免疫在oföchoroidal新生血管(CNV)相关diseasesù形成过程中的作用。炎症影响各种玻璃体视网膜疾病的形成和发展。我们对糖尿病性黄斑水肿、增殖性糖尿病视网膜病变、视网膜分支静脉阻塞、视网膜中央静脉阻塞和孔源性视网膜脱离的玻璃体液中的炎症免疫介质进行了全面分析。同时测定20种可溶性因子(9种细胞因子、6种趋化因子和5种生长因子)的浓度。在20个可溶性因子中,有3个因子:白细胞介素-6 (IL-6)、白细胞介素-8 (IL-8)和单核细胞化学引诱蛋白-1 (MCP-1)在所有玻璃体视网膜疾病组中与对照组相比显著升高。根据个体患者水平的相关性分析,这三个因素同时升高,在所有被检查的疾病中均未显示出任何独立的上调。我们还阐明了自然杀伤(NK)T细胞在激光诱导的实验性CNV中的作用,NK T细胞限制CD1分子并参与先天免疫反应。我们在两个独立的NKT细胞缺陷小鼠(CD1敲除(KO)小鼠或Ja18 KOmice)中检测了CNV的形成,发现两种KO小鼠的实验CNV都显著减少。在CNV相关疾病的临床过程中,除了CNV的形成外,视网膜下的瘢痕形成被认为是另一个重要的步骤。因此,我们通过向视网膜下间隙注射腹腔渗出性巨噬细胞建立视网膜下瘢痕的实验模型。接种后7天,用眼底镜观察小鼠视网膜下纤维组织。组织呈单调低细胞密度区,表达a-SMA,胶原合成。由于epec接种的MCP-1 KO小鼠胶质细胞残留量较少,因此除了外源性巨噬细胞外,内源性巨噬细胞也至关重要。活化的巨噬细胞在体外直接诱导RPE细胞的肌纤维化改变。
{"title":"Natural Immunity and Ocular Inflammation.","authors":"Koh-Hei Sonoda","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>We have focused on the role of innate immunity during the formation oföchoroidal neovascularization\u0000(CNV) -related diseasesù. Inflammation affects the formation and the progression of various\u0000vitreoretinal diseases. We performed a comprehensive analysis of inflammatory immune mediators in\u0000the vitreous fluids with diabetic macular edema, proliferative diabetic retinopathy, branch retinal vein\u0000occlusion, central retinal vein occlusion and rhegmatogenous retinal detachment. The concentrations\u0000of 20 soluble factors (nine cytokines, six chemokines, and five growth factors) were measured\u0000simultaneously by multiplex bead analysis system. Out of 20 soluble factors, three factors :\u0000interleukin-6 (IL-6), interleukin-8 (IL-8), and monocyte chemoattractant protein-1 (MCP-1) were\u0000significantly elevated in all groups of vitreoretinal diseases compared with control group. According to\u0000the correlation analysis in the individual patientʼs level, these three factors that were simultaneously\u0000increased, did not show any independent upregulation in all the examined diseases.\u0000We also elucidated the role of natural killer (NK)T cells, which restricted CD1 molecule and\u0000participate in the innate immune response, in laser-induced experimental CNV. We examined CNV\u0000formation in independent two NKT cell-deficient mice, either CD1 knockout (KO) mice or Ja18 KO\u0000mice, and found that both KO mice showed significant reduction of experimental CNV.\u0000During the clinical process of CNV-related diseases, not only CNV formation, subretinal scaring is\u0000thought to be another important step. We thus established the experimental model of subretinal\u0000scaring by injecting peritoneal exudating macrophages into subretinal space. Subretinal fibrous tissue\u0000was observed by fundus scope in PEC-inoculated mice after seven days. The tissue was consisted of\u0000monotonous and low cell-density area, which expressed a-SMA with collagen synthesis. Because\u0000PEC-inoculated MCP-1 KO mice showed less amount of glial residual, not only exogenous\u0000macrophages, but also intrinsic macrophages are critical. Activated macrophages directly induced\u0000myofibrotic changes in RPE cells in vitro.</p>","PeriodicalId":12665,"journal":{"name":"Fukuoka igaku zasshi = Hukuoka acta medica","volume":"107 12","pages":"205-12"},"PeriodicalIF":0.0,"publicationDate":"2016-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35240053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Molecular Mechanism of Lifestyle-related Diseases : See Both the Wood and Trees! 与生活方式有关的疾病的分子机制:看木材和树木!
Yoshihiro Ogawa

Energy homeostasis is maintained locally through parenchymal-stromal cell interaction and systemically through metabolic organ network. In obese adipose tissue, saturated fatty acids, which are released as a danger signal from hypertrophied adipocytes, stimulates a pathogen sensor TLR4 in the infiltrating macrophages, thus establishing a vicious cycle between adipocytes and macrophages to stimulate adipose tissue inflammation. Histologically, macrophages aggregate to constitute crown-like structures (CLS), where they are thought to scavenge the residual lipid droplets of dead adipocytes. Free fatty acids, when released from obese visceral fat depots, are transported in large quantities to the liver via the portal vein, where they are accumulated as ectopic fat, thus developing non-alcoholic fatty liver disease (NAFLD). There is a unique histological feature termed÷hepatic CLS (hCLS)øin the non-alcoholic steatohepatitis (NASH) liver, where macrophages aggregate to surround dead hepatocytes with large lipid droplets. Notably, the number of hCLS is positively correlated with the extent of liver fibrosis. Our data suggest that hCLS serves as an origin of hepatic inflammation and fibrosis during the progression from simple steatosis to NASH. Sodium glucose cotransporter 2 (SGLT2) inhibitors, an oral antidiabetic drug, promotes the urinaryexcretion of glucose by blocking its reabsorption in renal proximal tubules. Inhibition of SGLT2 lowers is expected to reduce body weight because of urinary calorie loss. Interestingly, SGLT2 inhibitionimproves hepatic steatosis in obese mice irrespective of body weight reduction. There is an inverse correlation between liver weight and adipose tissue weight in obese mice with SGLT2 inhibition, suggesting that SGLT2 inhibition induces the÷healthyøadipose tissue expansion and prevents ectopic fat accumulation in the liver. Our data suggest that seeing both the wood and trees is Required to understand the molecular mechanism of lifestyle-related diseases.

能量稳态是局部通过实质-间质细胞相互作用维持,全身通过代谢器官网络维持。在肥胖脂肪组织中,饱和脂肪酸作为一种危险信号从肥大的脂肪细胞中释放出来,刺激浸润的巨噬细胞中的病原体传感器TLR4,从而在脂肪细胞和巨噬细胞之间建立了刺激脂肪组织炎症的恶性循环。组织学上,巨噬细胞聚集形成冠状结构(CLS),在那里它们被认为是清除死亡脂肪细胞残留的脂滴。游离脂肪酸从肥胖的内脏脂肪库中释放出来后,通过门静脉大量转运到肝脏,在那里积聚为异位脂肪,从而发展为非酒精性脂肪肝(NAFLD)。在非酒精性脂肪性肝炎(NASH)肝脏中有一个独特的组织学特征termed÷hepatic CLS (hCLS)ø,巨噬细胞聚集在死亡的肝细胞周围形成大脂滴。值得注意的是,hCLS的数量与肝纤维化程度呈正相关。我们的数据表明,在从单纯脂肪变性到NASH的过程中,hCLS是肝脏炎症和纤维化的起源。葡萄糖共转运蛋白2钠(SGLT2)抑制剂是一种口服降糖药,通过阻断葡萄糖在肾近端小管的重吸收来促进葡萄糖的尿排泄。抑制SGLT2的降低有望减少体重,因为尿热量损失。有趣的是,SGLT2抑制改善了肥胖小鼠的肝脏脂肪变性,而与体重减轻无关。SGLT2抑制的肥胖小鼠肝脏重量与脂肪组织重量呈负相关,提示SGLT2抑制诱导the÷healthyøadipose组织扩张,防止肝脏内异位脂肪堆积。我们的数据表明,要了解与生活方式有关的疾病的分子机制,需要同时观察木材和树木。
{"title":"Molecular Mechanism of Lifestyle-related Diseases : See Both the Wood and Trees!","authors":"Yoshihiro Ogawa","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Energy homeostasis is maintained locally through parenchymal-stromal cell interaction and systemically through metabolic organ network. In obese adipose tissue, saturated fatty acids, which are released as a danger signal from hypertrophied adipocytes, stimulates a pathogen sensor TLR4 in the infiltrating macrophages, thus establishing a vicious cycle between adipocytes and macrophages to stimulate adipose tissue inflammation. Histologically, macrophages aggregate to constitute crown-like structures (CLS), where they are thought to scavenge the residual lipid droplets of dead adipocytes. Free fatty acids, when released from obese visceral fat depots, are transported in large quantities to the liver via the portal vein, where they are accumulated as ectopic fat, thus developing non-alcoholic fatty liver disease (NAFLD). There is a unique histological feature termed÷hepatic CLS (hCLS)øin the non-alcoholic steatohepatitis (NASH) liver, where macrophages aggregate to surround dead hepatocytes with large lipid droplets. Notably, the number of hCLS is positively correlated with the extent of liver fibrosis. Our data suggest that hCLS serves as an origin of hepatic inflammation and fibrosis during the progression from simple steatosis to NASH. Sodium glucose cotransporter 2 (SGLT2) inhibitors, an oral antidiabetic drug, promotes the urinaryexcretion of glucose by blocking its reabsorption in renal proximal tubules. Inhibition of SGLT2 lowers is expected to reduce body weight because of urinary calorie loss. Interestingly, SGLT2 inhibition\u0000improves hepatic steatosis in obese mice irrespective of body weight reduction. There is an inverse correlation between liver weight and adipose tissue weight in obese mice with SGLT2 inhibition, suggesting that SGLT2 inhibition induces the÷healthyøadipose tissue expansion and prevents ectopic fat accumulation in the liver. Our data suggest that seeing both the wood and trees is Required to understand the molecular mechanism of lifestyle-related diseases.</p>","PeriodicalId":12665,"journal":{"name":"Fukuoka igaku zasshi = Hukuoka acta medica","volume":"107 11","pages":"191-8"},"PeriodicalIF":0.0,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35240051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunohistological Localization of Peroxisome Proliferator-Activated Receptor α and γ in Human Sebaceous Glands. 人皮脂腺过氧化物酶体增殖物激活受体α和γ的免疫组织学定位。
Masutake Furue, Masaki Takemura, Kiichiroet Nishio, Yuki Sato, Shoko Nagata, Nagisa Kan, Asako Suenaga, Kazuhisa Furue, Maiko Yoshida, Sawako Konishi, Gaku Tsuji

The immunohistological localization of peroxisome proliferator-activated receptor a (PPARa) and PPAR g was examined in 28 pilosebaceous units in 10 paraffin-embedded normal human skin specimens. Rabbit polyclonal antibody against human PPARa and monoclonal antibody against human PPARg were used as specific primary antibodies. The nuclear and cytoplasmic expression of PPARa was detected in basal to differentiated sebocytes. In contrast, the expression of PPARg was confined to nuclei of suprabasal to early-differentiated sebocytes. The nuclear PPARg expression was present only occasionally in the basal sebocytes. These results suggest that PPARa and PPARg are integral parts of sebocyte differentiation in human sebaceous glands.

对10例正常人皮肤标本中28个毛囊皮脂腺单位的过氧化物酶体增殖物激活受体a (PPAR)和PPAR g进行了免疫组织学定位检测。特异性一抗采用兔抗人PPARa多克隆抗体和人PPARa单克隆抗体。PPARa的核表达和细胞质表达在基础和分化的皮脂细胞中被检测到。相比之下,PPARg的表达仅限于基底上至早期分化的皮脂细胞的细胞核。核PPARg表达仅偶尔出现在基底脂细胞中。这些结果表明,PPARa和PPARg是人皮脂腺皮脂细胞分化的重要组成部分。
{"title":"Immunohistological Localization of Peroxisome Proliferator-Activated Receptor α and γ in Human Sebaceous Glands.","authors":"Masutake Furue,&nbsp;Masaki Takemura,&nbsp;Kiichiroet Nishio,&nbsp;Yuki Sato,&nbsp;Shoko Nagata,&nbsp;Nagisa Kan,&nbsp;Asako Suenaga,&nbsp;Kazuhisa Furue,&nbsp;Maiko Yoshida,&nbsp;Sawako Konishi,&nbsp;Gaku Tsuji","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The immunohistological localization of peroxisome proliferator-activated receptor a (PPARa) and PPAR g was examined in 28 pilosebaceous units in 10 paraffin-embedded normal human skin specimens. Rabbit polyclonal antibody against human PPARa and monoclonal antibody against human PPARg were used as specific primary antibodies. The nuclear and cytoplasmic expression of PPARa was detected in basal to differentiated sebocytes. In contrast, the expression of PPARg was confined to nuclei of suprabasal to early-differentiated sebocytes. The nuclear PPARg expression was present only occasionally in the basal sebocytes. These results suggest that PPARa and PPARg are integral parts of sebocyte differentiation in human sebaceous glands.</p>","PeriodicalId":12665,"journal":{"name":"Fukuoka igaku zasshi = Hukuoka acta medica","volume":"107 11","pages":"199-203"},"PeriodicalIF":0.0,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35240052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Portal Vein Thrombosis Repeatedly Observed in a Cirrhotic Patient with Antiphospholipid Antibody Syndrome. 肝硬化伴抗磷脂抗体综合征患者反复观察门静脉血栓形成。
Mari Ohe, Taishi Mutsuki, Takeshi Goya, Shinsaku Yamashita, Takeaki Satoh, Motoyuki Kohjima, Masaki Kato

Background: Although portal vein thrombosis in cirrhotic patients is frequently observed, thedetailed process remains to be clarified, and the role of anticardiolipin antibody in the development ofportal vein thrombosis has been controversial.

Case report: A 52-year-old man, who had been diagnosed with alcoholic cirrhosis of the liver, wasadmitted to our hospital suffering from dyspnea and ascites. Just after being diagnosed as havingantiphospholipid antibody syndrome with lung thrombosis and delivering a positive result for the β2-glycoprotein I-dependent anticardiolipin antibody, he sustained rupture of the esophageal variceswith rapid development of portal vein thrombosis, which resolved under anticoagulant therapy. Twoyears later, he was admitted again on suspicion of thrombosis because of an elevation in the serumD-dimer level, and computed tomography showed portal and upper mesenteric vein thrombosis.Although immediate anticoagulant therapy resulted in complete recanalization, he suffered the sameepisode 2 months later, which occurred with re-elevation of the serum D-dimer level.

Conclusion: A positive finding of an anticardiolipin antibody in cirrhotic patients has been consideredto be nonspecific and not related to the development of thrombus in the portal vein. This case,however, seems to indicate that cirrhotic patients with the β2-glycoprotein I-dependentanticardiolipin antibody should be regarded as being at high risk for portal vein thrombosis. Monitoringwith the serum D-dimer was useful in detecting portal vein thrombosis in its early stage.

背景:虽然肝硬化患者经常观察到门静脉血栓形成,但其具体过程尚不清楚,抗心磷脂抗体在门静脉血栓形成发展中的作用一直存在争议。病例报告:一名52岁男性,诊断为酒精性肝硬化,因呼吸困难和腹水入院。在被诊断为抗磷脂抗体综合征伴肺血栓形成,β2-糖蛋白i依赖性抗心磷脂抗体阳性后,他出现食管静脉曲张破裂,门静脉血栓形成迅速发展,经抗凝治疗后消退。两年后,由于血清d -二聚体水平升高,怀疑血栓形成再次入院,计算机断层扫描显示门静脉和上肠系膜静脉血栓形成。虽然立即抗凝治疗导致完全再通,但2个月后,患者再次出现相同的发作,发生在血清d -二聚体水平再次升高时。结论:肝硬化患者抗心磷脂抗体阳性被认为是非特异性的,与门静脉血栓的形成无关。然而,该病例似乎表明,肝硬化患者β2-糖蛋白i依赖性抗心磷脂抗体应被视为门静脉血栓形成的高危人群。血清d -二聚体监测有助于早期发现门静脉血栓形成。
{"title":"Portal Vein Thrombosis Repeatedly Observed in a Cirrhotic Patient with Antiphospholipid Antibody Syndrome.","authors":"Mari Ohe,&nbsp;Taishi Mutsuki,&nbsp;Takeshi Goya,&nbsp;Shinsaku Yamashita,&nbsp;Takeaki Satoh,&nbsp;Motoyuki Kohjima,&nbsp;Masaki Kato","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Although portal vein thrombosis in cirrhotic patients is frequently observed, the\u0000detailed process remains to be clarified, and the role of anticardiolipin antibody in the development of\u0000portal vein thrombosis has been controversial.</p><p><strong>Case report: </strong>A 52-year-old man, who had been diagnosed with alcoholic cirrhosis of the liver, was\u0000admitted to our hospital suffering from dyspnea and ascites. Just after being diagnosed as having\u0000antiphospholipid antibody syndrome with lung thrombosis and delivering a positive result for the β\u00002-glycoprotein I-dependent anticardiolipin antibody, he sustained rupture of the esophageal varices\u0000with rapid development of portal vein thrombosis, which resolved under anticoagulant therapy. Two\u0000years later, he was admitted again on suspicion of thrombosis because of an elevation in the serum\u0000D-dimer level, and computed tomography showed portal and upper mesenteric vein thrombosis.\u0000Although immediate anticoagulant therapy resulted in complete recanalization, he suffered the same\u0000episode 2 months later, which occurred with re-elevation of the serum D-dimer level.</p><p><strong>Conclusion: </strong>A positive finding of an anticardiolipin antibody in cirrhotic patients has been considered\u0000to be nonspecific and not related to the development of thrombus in the portal vein. This case,\u0000however, seems to indicate that cirrhotic patients with the β2-glycoprotein I-dependent\u0000anticardiolipin antibody should be regarded as being at high risk for portal vein thrombosis. Monitoring\u0000with the serum D-dimer was useful in detecting portal vein thrombosis in its early stage.</p>","PeriodicalId":12665,"journal":{"name":"Fukuoka igaku zasshi = Hukuoka acta medica","volume":"107 10","pages":"185-90"},"PeriodicalIF":0.0,"publicationDate":"2016-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35240050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Portal Vein Thrombosis Repeatedly Observed in a Cirrhotic Patient with Antiphospholipid Antibody Syndrome. 肝硬化伴抗磷脂抗体综合征患者反复观察门静脉血栓形成。
Pub Date : 2016-10-01 DOI: 10.15017/1792722
M. Ohe, Taishi Mutsuki, T. Goya, Shinsaku Yamashita, T. Satoh, M. Kohjima, Masaki Kato
BackgroundAlthough portal vein thrombosis in cirrhotic patients is frequently observed, thedetailed process remains to be clarified, and the role of anticardiolipin antibody in the development ofportal vein thrombosis has been controversial.Case ReportA 52-year-old man, who had been diagnosed with alcoholic cirrhosis of the liver, wasadmitted to our hospital suffering from dyspnea and ascites. Just after being diagnosed as havingantiphospholipid antibody syndrome with lung thrombosis and delivering a positive result for the β2-glycoprotein I-dependent anticardiolipin antibody, he sustained rupture of the esophageal variceswith rapid development of portal vein thrombosis, which resolved under anticoagulant therapy. Twoyears later, he was admitted again on suspicion of thrombosis because of an elevation in the serumD-dimer level, and computed tomography showed portal and upper mesenteric vein thrombosis.Although immediate anticoagulant therapy resulted in complete recanalization, he suffered the sameepisode 2 months later, which occurred with re-elevation of the serum D-dimer level.ConclusionA positive finding of an anticardiolipin antibody in cirrhotic patients has been consideredto be nonspecific and not related to the development of thrombus in the portal vein. This case,however, seems to indicate that cirrhotic patients with the β2-glycoprotein I-dependentanticardiolipin antibody should be regarded as being at high risk for portal vein thrombosis. Monitoringwith the serum D-dimer was useful in detecting portal vein thrombosis in its early stage.
背景虽然肝硬化患者经常观察到门静脉血栓形成,但其具体过程尚不清楚,抗心磷脂抗体在门静脉血栓形成发展中的作用一直存在争议。病例报告一例52岁男性,诊断为酒精性肝硬化,因呼吸困难和腹水入住我院。在被诊断为抗磷脂抗体综合征伴肺血栓形成,β2-糖蛋白i依赖性抗心磷脂抗体阳性后,他出现食管静脉曲张破裂,门静脉血栓形成迅速发展,经抗凝治疗后消退。两年后,由于血清d -二聚体水平升高,怀疑血栓形成再次入院,计算机断层扫描显示门静脉和上肠系膜静脉血栓形成。虽然立即抗凝治疗导致完全再通,但2个月后,患者再次出现相同的发作,发生在血清d -二聚体水平再次升高时。结论肝硬化患者抗心磷脂抗体阳性被认为是非特异性的,与门静脉血栓的形成无关。然而,该病例似乎表明,肝硬化患者β2-糖蛋白i依赖性抗心磷脂抗体应被视为门静脉血栓形成的高危人群。血清d -二聚体监测有助于早期发现门静脉血栓形成。
{"title":"Portal Vein Thrombosis Repeatedly Observed in a Cirrhotic Patient with Antiphospholipid Antibody Syndrome.","authors":"M. Ohe, Taishi Mutsuki, T. Goya, Shinsaku Yamashita, T. Satoh, M. Kohjima, Masaki Kato","doi":"10.15017/1792722","DOIUrl":"https://doi.org/10.15017/1792722","url":null,"abstract":"Background\u0000Although portal vein thrombosis in cirrhotic patients is frequently observed, the\u0000detailed process remains to be clarified, and the role of anticardiolipin antibody in the development of\u0000portal vein thrombosis has been controversial.\u0000\u0000\u0000Case Report\u0000A 52-year-old man, who had been diagnosed with alcoholic cirrhosis of the liver, was\u0000admitted to our hospital suffering from dyspnea and ascites. Just after being diagnosed as having\u0000antiphospholipid antibody syndrome with lung thrombosis and delivering a positive result for the β\u00002-glycoprotein I-dependent anticardiolipin antibody, he sustained rupture of the esophageal varices\u0000with rapid development of portal vein thrombosis, which resolved under anticoagulant therapy. Two\u0000years later, he was admitted again on suspicion of thrombosis because of an elevation in the serum\u0000D-dimer level, and computed tomography showed portal and upper mesenteric vein thrombosis.\u0000Although immediate anticoagulant therapy resulted in complete recanalization, he suffered the same\u0000episode 2 months later, which occurred with re-elevation of the serum D-dimer level.\u0000\u0000\u0000Conclusion\u0000A positive finding of an anticardiolipin antibody in cirrhotic patients has been considered\u0000to be nonspecific and not related to the development of thrombus in the portal vein. This case,\u0000however, seems to indicate that cirrhotic patients with the β2-glycoprotein I-dependent\u0000anticardiolipin antibody should be regarded as being at high risk for portal vein thrombosis. Monitoring\u0000with the serum D-dimer was useful in detecting portal vein thrombosis in its early stage.","PeriodicalId":12665,"journal":{"name":"Fukuoka igaku zasshi = Hukuoka acta medica","volume":"32 1","pages":"185-90"},"PeriodicalIF":0.0,"publicationDate":"2016-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87191923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
期刊
Fukuoka igaku zasshi = Hukuoka acta medica
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1